Source: National Institutes of Health
By: Fauci, Anthony S.
The ROTAVAC rotavirus vaccine trial in India was a success, according to Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), which was part of the public/private collaboration that developed and tested the vaccine. The vaccine was developed using the 116E vaccine strain provided by NIAID to Bharat Biotech International Ltd., which adapted the strain and created the investigational vaccines. With the help of funding from the Program for Appropriate Technology in Health, NIAID sponsored three Phase I studies of the live, attenuated 116E rotavirus vaccine in India, which involved adults, children between the ages of two and 12 years, and infants aged six to nine weeks. As a result of the successful study, a licensed vaccine that will protect infants against severe rotavirus-induced gastroenteritis will become available in India.